The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane. The risk or severity of adverse effects can be increased when Lisuride is combined with Olanzapine. The risk or severity of adverse effects can be increased when Dienestrol is combined with Ospemifene. Betaxolol may decrease the bronchodilatory activities of Vilanterol. The risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril. Amobarbital may increase the hypotensive activities of Bumetanide. The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tixocortol. The serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin. The risk or severity of adverse effects can be increased when Nitrendipine is combined with Reserpine. The risk or severity of adverse effects can be increased when Nimesulide is combined with Serrapeptase. The serum concentration of Sulfadiazine can be decreased when it is combined with Cyproterone acetate. The serum concentration of Imipramine can be increased when it is combined with Zofenopril. The risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide. The risk or severity of adverse effects can be increased when Fentanyl is combined with Bromazepam. The metabolism of Pentobarbital can be decreased when combined with Moclobemide. The risk or severity of adverse effects can be increased when Ethanol is combined with Methylene blue. Prazosin may increase the hypotensive activities of Nilvadipine. The therapeutic efficacy of Alprostadil can be decreased when used in combination with Phenylbutazone. The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide. Secobarbital may increase the hypotensive activities of Clofarabine. Methohexital may increase the hypotensive activities of Benazepril. Oxyphenonium may increase the tachycardic activities of Dronabinol. The serum concentration of Methallenestril can be decreased when it is combined with Trandolapril. The risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol. Avanafil may increase the antihypertensive activities of Tolazoline. Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine. Adapalene may decrease the excretion rate of Amikacin which could result in a higher serum level. The therapeutic efficacy of Norgestrel can be decreased when used in combination with Methylphenobarbital. The risk or severity of adverse effects can be increased when Opium is combined with Tolcapone. The serum concentration of Budesonide can be increased when it is combined with Stiripentol. Dobutamine may increase the hypokalemic activities of Bendroflumethiazide. The serum concentration of Methallenestril can be decreased when it is combined with Oxcarbazepine. The serum concentration of Amobarbital can be increased when it is combined with Valproic Acid. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocabastine. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin. The risk or severity of adverse effects can be increased when Lisofylline is combined with Fluprednidene. The metabolism of Artemether can be decreased when combined with Eslicarbazepine acetate. Lumiracoxib may decrease the antihypertensive activities of Nebivolol. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Clomifene resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Hydrochlorothiazide. The therapeutic efficacy of Phenformin can be decreased when used in combination with Lanreotide. The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Drospirenone. The serum concentration of Atorvastatin can be increased when it is combined with Sitagliptin. The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Polythiazide. The bioavailability of Aldosterone can be decreased when combined with Magnesium oxide. The therapeutic efficacy of Polythiazide can be decreased when used in combination with Tiaprofenic acid. The metabolism of Daunorubicin can be decreased when combined with Cobicistat. The risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil. The risk or severity of adverse effects can be increased when Alclofenac is combined with Tixocortol. Magaldrate may decrease the excretion rate of Midomafetamine which could result in a higher serum level. The serum concentration of Lorcaserin can be increased when it is combined with Cobicistat. Formoterol may increase the QTc-prolonging activities of Saquinavir. Clobetasone may increase the fluid retaining activities of GLPG-0492. The serum concentration of Bosentan can be increased when it is combined with Ritonavir. Alprostadil may increase the anticoagulant activities of Cangrelor. The metabolism of Triamcinolone can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide. The risk or severity of adverse effects can be increased when Rofecoxib is combined with Budesonide. Diflunisal may decrease the antihypertensive activities of Moexipril. The serum concentration of Lurasidone can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Brimonidine is combined with Nitroglycerin. The metabolism of Dextromethorphan can be decreased when combined with Tolbutamide. The metabolism of Lercanidipine can be increased when combined with Nafcillin. The risk or severity of adverse effects can be increased when Risperidone is combined with Dextropropoxyphene. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desloratadine. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone. The metabolism of Rupatadine can be decreased when combined with Ketoconazole. Azelastine may decrease the antihypertensive activities of Hydralazine. Nicardipine may increase the QTc-prolonging activities of Azithromycin. The serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine. Diazoxide may increase the hypotensive activities of Rituximab. The risk or severity of adverse effects can be increased when Atropine is combined with Tropicamide. The metabolism of Apixaban can be decreased when combined with Tenofovir disoproxil. The metabolism of Domperidone can be decreased when combined with Losartan. Naphazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol. The risk or severity of adverse effects can be increased when Hexetidine is combined with Lamotrigine. Phenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide. Indapamide may increase the hypotensive activities of Nitrendipine. The risk or severity of adverse effects can be increased when Isradipine is combined with Nadolol. Etanercept may decrease the antihypertensive activities of Metipranolol. Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ritonavir. Alprostadil may increase the anticoagulant activities of Dextran 75. Penbutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide. The serum concentration of Prednisolone can be increased when it is combined with Cobicistat. Indacaterol may increase the QTc-prolonging activities of Domperidone. The metabolism of Riociguat can be decreased when combined with Rosiglitazone. The risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon. The serum concentration of Fluocinonide can be increased when it is combined with Dienestrol. Digoxin may decrease the cardiotoxic activities of Aflibercept. Octreotide may increase the bradycardic activities of Pindolol. Rofecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level. The metabolism of Buprenorphine can be increased when combined with Nevirapine. The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Diethylstilbestrol. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Codeine. The risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylic acid. The metabolism of Pilocarpine can be decreased when combined with Fluconazole. Azelastine may decrease the antihypertensive activities of Practolol. The metabolism of Cytarabine can be decreased when combined with Cobicistat. The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide. Zofenopril may increase the hypotensive activities of Amifostine. The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Dexamethasone. Chlorothiazide may increase the hypotensive activities of Vincamine. The metabolism of Olodaterol can be decreased when combined with Valproic Acid. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa. Magnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Sulindac may decrease the excretion rate of Framycetin which could result in a higher serum level. The serum concentration of Diphenhydramine can be increased when it is combined with Darunavir. The metabolism of Levomilnacipran can be decreased when combined with Verapamil. Meclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level. The serum concentration of Flurandrenolide can be decreased when it is combined with Lumacaftor. The metabolism of Ximelagatran can be decreased when combined with Sulfisoxazole. The metabolism of Ketoconazole can be decreased when combined with Clemastine. The therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline. The risk or severity of adverse effects can be increased when Methaqualone is combined with Adipiplon. The metabolism of Triamcinolone can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide. The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketobemidone. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Everolimus. The risk or severity of adverse effects can be increased when Moxonidine is combined with Bumetanide. The risk or severity of adverse effects can be increased when Clorazepate is combined with Etidocaine. The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b. The metabolism of Antipyrine can be decreased when combined with Tipranavir. The metabolism of Tacrolimus can be decreased when combined with Hexetidine. The risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite. The metabolism of Progesterone can be decreased when combined with Cocaine. The metabolism of Piroxicam can be decreased when combined with Zafirlukast. Saxagliptin may increase the hypoglycemic activities of Sunitinib.